Compare KBH & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KBH | CRSP |
|---|---|---|
| Founded | 1957 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.4B |
| IPO Year | 1994 | 2016 |
| Metric | KBH | CRSP |
|---|---|---|
| Price | $52.94 | $46.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $61.70 | ★ $70.29 |
| AVG Volume (30 Days) | 846.1K | ★ 2.0M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.15 | N/A |
| Revenue | ★ $4,547,002,000.00 | $289,590,000.00 |
| Revenue This Year | N/A | $1,082.59 |
| Revenue Next Year | $6.00 | $87.74 |
| P/E Ratio | $8.29 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $49.70 | $30.06 |
| 52 Week High | $68.71 | $78.48 |
| Indicator | KBH | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 38.46 |
| Support Level | $50.07 | N/A |
| Resistance Level | $56.50 | $60.63 |
| Average True Range (ATR) | 1.51 | 2.32 |
| MACD | -0.35 | -0.84 |
| Stochastic Oscillator | 29.92 | 10.48 |
KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.